A Phase 4 interventional study of Sildenafil in Pulmonary Arterial Hypertension and Hypertension, Pulmonary, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 5 sites in Japan. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2021-02-01.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing sildenafil in Pulmonary Arterial Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Pulmonary Arterial Hypertension.
Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, this one is the 17th largest by enrollment, is the only one that started in 2012, is one of 6 in phase 4, and was the 15th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 18 studies testing sildenafil in Pulmonary Arterial Hypertension is open now, in 1 country. Recruiting first, the newest first:
Silvia Ulrich · Sites in Switzerland
Ages 18–80
By country, each count listing its studies:
sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 8 · Phase 4 6
First in 2002; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 23 across the 18 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
14 studies in Pulmonary Arterial Hypertension by Viatris Inc.: none open now, none under way, none of them phase 3. Of 9 finished, 8 (89%) have results posted.
Among the 14 studies in Pulmonary Arterial Hypertension by Viatris Inc., this one is the only one that started in 2012, is one of 4 in phase 4, and was the 10th registered.
Viatris Inc.’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 14 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening disease. In many patients, the course of PAH is a steady deterioration and reduced life expectancy.
Sildenafil was approved by the European Commission for the treatment of PAH in pediatric patients in May 2011, making it the first agent to be approved for the treatment of children with PAH. The approval was based on the largest placebo-controlled study to be conducted in this population. The recommended dose in pediatric patients aged 1 year to 17 years old is 10 mg TID in patients ≤ 20 kg and 20 mg TID for patients > 20 kg. Higher doses are not recommended in pediatrics patients.
This study is an open-label, multi-center study to investigate safety, efficacy and pharmacokinetics of sildenafil citrate in Japanese pediatric patients with PAH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Sildenafil
Body weight \> 20 kg: 20 mg TID (60 mg/day) Body weight ≤ 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2
Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) at Week 16
PVRI equals pulmonary vascular resistance (PVR) times body surface area (BSA) (PVRI = PVR\*BSA). PVR is the resistance to blood flow through the pulmonary circulation and it was measured in Wood units. Wood unit =80 dyne\*seconds per centimetre\^5 (dyne\*sec/cm\^5).
Time frame: Baseline, Week 16
Change From Baseline in Mean Pulmonary Artery Pressure (mPAP) at Week 16
It was a hemodynamic parameter and measured using a pressure transducer positioned at the mid-axillary line with the participant in the supine position.
Time frame: Baseline, Week 16
Change From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Week 4
WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported.
Time frame: Baseline, Week 4
Change From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Week 8
WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported.
Time frame: Baseline, Week 8
Change From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Week 16
WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported.
Time frame: Baseline, Week 16
Change From Baseline in Brain Natriuretic Peptide (BNP) at Week 16
BNP is produced by ventricular cardiomyocytes. It causes reduction in preload and blood pressure by vasodilatation.
Time frame: Baseline, Week 16
Change From Baseline in N-terminal Pro Brain Natriuretic Peptide (NT Pro-BNP) at Week 16
NT pro-BNP is a cardiac marker, having the prognostic value for participants with heart failure or left ventricular dysfunction. Higher level of the marker was indicative of heart damage.
Time frame: Baseline, Week 16
Change From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Weeks 28, 40, 52, 64, 76, 88, 100, 112 and 124
WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported.
Time frame: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, 100, 112 and 124
Change From Baseline in Brain Natriuretic Peptide (BNP) at Week 52 and End of Treatment (EOT)
BNP is produced by ventricular cardiomyocytes. It causes reduction in preload and blood pressure by vasodilatation.
Time frame: Baseline, Week 52 and End of treatment (maximum duration of treatment: 119.6 weeks)
Change From Baseline in N-terminal Pro Brain Natriuretic Peptide (NT Pro-BNP) at Week 52 and End of Treatment (EOT)
NT pro-BNP is a cardiac marker, having the prognostic value for participants with heart failure or left ventricular dysfunction. Higher level of the marker was indicative of heart damage.
Time frame: Baseline, Week 52 and End of treatment (maximum duration of treatment: 119.6 weeks)
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-serious AEs.
Time frame: Baseline upto 28 days after last dose of study drug (maximum duration of treatment: 119.6 weeks)
Number of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-serious AEs.
Time frame: Baseline upto 28 days after last dose of study drug (maximum duration of treatment: 119.6 weeks)
Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, 100, 112 and 124
BP measurement is recorded as supine and sitting systolic and diastolic systemic blood pressure: 1) Systolic blood pressure when heart is contracting and it is the maximum arterial pressure during contraction of left ventricle. 2) Diastolic BP when heart is relaxing and it is the minimum arterial pressure during relaxation and dilation of ventricles. Only those categories in which at least 1 participant had data were reported.
Time frame: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, 100, 112 and 124
Change From Baseline in Heart Rate at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, 100, 112 and 124
Only those categories in which at least 1 participant had data were reported.
Time frame: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, 100, 112 and 124
Number of Participants With Laboratory Abnormalities
Laboratory abnormality criteria: Hematology (hemoglobin, hematocrit, red blood cell count \[less than {\<}\]0.8\*lower limit of normal \[LLN\]; platelets \<0.5\*LLN, greater than \[\>\]1.75\*upper limit of normal \[ULN\], white blood cells \<0.6\*LLN, \>1.5\*ULN; lymphocytes, neutrophils \<0.8\*LLN, \>1.2\*ULN, eosinophils, basophils, monocytes \>1.2\*ULN); liver function (total and direct bilirubin \>1.5\*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN, total protein, albumin \<0.8\*LLN, \>1.2\*ULN); renal (creatinine, blood urea nitrogen \>1.3\*ULN); electrolytes (sodium \<0.95\*LLN, \>1.05\*ULN, potassium, chloride \<0.9\*LLN, \>1.1\*ULN; other (glucose \<0.6\*LLN or \>1.5\*ULN ); urinalysis (dipstick) urine glucose, urine protein, urine blood/Hemoglobin, \[greater than or equal to {\>=}1\].
Time frame: Baseline up-to End of treatment (maximum duration of treatment: 119.6 weeks)
Number of Participants With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities
Criteria for clinically significant abnormality in ECG parameters: Maximum corrected QT interval (QTc) from 450 millisecond (msec) to less than (\<) 480 msec, Maximum QTcB interval (Bazett's Correction) from 450 msec to \<480 msec, Maximum QTcF interval (Fredericia's Correction) from 450 msec to \<480 msec, maximum QTc interval increase from baseline of 30 msec to \<60 msec and \>=60 msec.
Time frame: Screening, Week 16, Week 52 and End of treatment (maximum duration of treatment: 119.6 weeks)
Number of Participants With Ocular Examination Abnormalities
Ocular examination measures included external examination of the eye, funduscopy, assessments of visual acuity, and color vision. Ocular examination findings were considered abnormal based on investigator's decision.
Time frame: Screening up to end of treatment (maximum duration of treatment: 119.6 weeks)
Change From Baseline in Pulmonary Artery Systolic and Diastolic Pressure at Week 16
Time frame: Baseline, Week 16
Change From Baseline in Systemic Artery Systolic and Diastolic Pressure at Week 16
Time frame: Baseline, Week 16
Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 16
The resistance to blood flow through the pulmonary circulation is known as PVR. It is largely influenced by the caliber of the pulmonary arteries and capillaries and was measured in terms of Wood units. Wood unit =80 dyne\*seconds per centimetre\^5 (dyne\*sec/cm\^5).
Time frame: Baseline, Week 16
Change From Baseline in Right Atrial Pressure (RAP) at Week 16
RAP is the blood pressure in the right atrium of the heart. It reflects the amount of blood returning to the heart and the ability of the heart to pump the blood into the arterial system. RAP was measured using a pressure transducer positioned at the mid-axillary line with the participant in the supine position.
Time frame: Baseline, Week 16
Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 16
PCWP was measured by pulmonary artery catheterization and provided an indirect measure of left atrial pressure.
Time frame: Baseline, Week 16
Change From Baseline in Cardiac Output (CO) at Week 16
Cardiac output is simply the amount of blood pumped by the heart per minute.
Time frame: Baseline, Week 16
Change From Baseline in Cardiac Index (CI) at Week 16
Cardiac index is a hemodynamic parameter that relates the cardiac output from left ventricle in one minute to BSA, thus relating heart performance to the size of the individual. CI was calculated as cardiac output in systemic circulation divided by BSA.
Time frame: Baseline, Week 16
Change From Baseline in Systemic Vascular Resistance (SVR) at Week 16
The resistance to blood flow through the systemic circulation is known as SVR. This can be used in measuring blood pressure, blood flow and cardiac function and measured in terms of Wood units. Wood unit =80 dyne\*seconds per centimetre\^5 (dyne\*sec/cm\^5).
Time frame: Baseline, Week 16
Change From Baseline in Systemic Vascular Resistance Index (SVRI) at Week 16
SVRI equals systemic vascular resistance (SVR) times BSA. SVR is the resistance to blood flow through the systemic circulation and it was measured in Wood units. Wood unit =80 dyne\*seconds per centimetre\^5 (dyne\*sec/cm\^5).
Time frame: Baseline, Week 16
Change From Baseline in Mixed Venous Oxygen Saturation (SvO2) at Week 16
SvO2 is the percentage of mixed venous oxygen (amount of oxygen bound to hemoglobin in venous blood). Change from baseline in percentage of mixed venous oxygen was reported in this outcome measure.
Time frame: Baseline, Week 16
Change From Baseline in Arterial Oxygen Saturation (SaO2) at Week 16
SaO2 is the percentage of arterial oxygen (amount of oxygen bound to hemoglobin in arterial blood). Change from baseline in percentage of arterial oxygen was reported in this outcome measure.
Time frame: Baseline, Week 16
Maximum Observed Plasma Concentration (Cmax) of Sildenafil and UK-103,320
UK-103,320 was the main metabolite of Sildenafil and was produced by cytochrome P450 3A4.
Time frame: Pre-dose (0 hour) on Week 4, 8, 16 and 1, 2, 4, 8 hours post-dose on Week 16
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Sildenafil and UK-103,320
UK-103,320 was the main metabolite of Sildenafil and was produced by cytochrome P450 3A4.
Time frame: Pre-dose (0 hour) on Week 4, 8, 16 and 1, 2, 4, 8 hours post-dose on Week 16
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Sildenafil and UK-103,320
UK-103,320 was the main metabolite of Sildenafil and was produced by cytochrome P450 3A4.
Time frame: Pre-dose (0 hour) on Week 4, 8, 16 and 1, 2, 4, 8 hours post-dose on Week 16
Terminal Half Life (t1/2) of Sildenafil and UK-103,320
Terminal half-life is the time measured for the plasma concentration to decrease by one half of its original concentration. UK-103,320 was a main metabolite of sildenafil and was produced by cytochrome P450 3A4.
Time frame: Pre-dose (0 hour) on Week 4, 8, 16 and 1, 2, 4, 8 hours post-dose on Week 16
Apparent Oral Clearance (CL/F) of Sildenafil
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Time frame: Pre-dose (0 hour) on Week 4, 8, 16 and 1, 2, 4, 8 hours post-dose on Week 16
Apparent Volume of Distribution (Vz/F) of Sildenafil
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time frame: Pre-dose (0 hour) on Week 4, 8, 16 and 1, 2, 4, 8 hours post-dose on Week 16
Change From Baseline in Ratio of Acceleration Time to Ejection Time (AcT/ET) at Week 16
Acceleration time and ejection time are quantitative Doppler parameters and ratio of acceleration time to ejection time is a useful tool to evaluate the severity of aortic stenosis.
Time frame: Baseline, Week 16
Change From Baseline in Right Ventricular Tei Index at Week 16
The right ventricular Tei Index is an index of myocardial performance. It is defined as the sum of isovolumic contraction time and isovolumic relaxation time divided by the ejection time.
Time frame: Baseline, Week 16
Change From Baseline in Right Ventricular Size at Week 16
Time frame: Baseline, Week 16
Change From Baseline in Tricuspid Valve Annulus Size at Week 16
The tricuspid valve lies between the right atrium and the right ventricle and is placed in a more apical position than the mitral valve. The annulus separates the right atrium from the right ventricle. Change from baseline in tricuspid valve annulus size (in cm) was reported in this outcome measure.
Time frame: Baseline, Week 16
Change From Baseline in Tricuspid Regurgitation - Pressure Gradient (TR-PG) Peak at Week 16
Tricuspid regurgitation (insufficiency) is the failure of the tricuspid valve to close properly during systole, leading to the leaking of blood from the right ventricle into the right atrium. Change from baseline in TR-PG peak (in mmHg) was reported in this outcome measure.
Time frame: Baseline, Week 16
Change From Baseline in Pulmonary Regurgitation - Pressure Gradient (PR-PG) End-Diastole at Week 16
Pulmonary regurgitation (PR) or insufficiency is a valvular heart disease characterized by an incomplete closure of the pulmonary valve leading to a diastolic reflux into the right ventricle. Change from baseline in PR-PG end-diastole (in mmHg) was reported in this outcome measure.
Time frame: Baseline, Week 16
Number of Participants With Pericardial Effusion
Pericardial effusion is the presence of an abnormal amount of fluid in the pericardial cavity, as determined by echocardiography.
Time frame: Baseline up to Week 16
Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE) at Week 16
Tricuspid annular plane systolic excursion is a parameter depicting global right ventricular function. Change from baseline in TAPSE (in cm) was reported in this outcome measure.
Time frame: Baseline, Week 16
| Milestone | Sildenafil |
|---|---|
| Started | 6 |
| Completed | 3 |
| Not completed | 3 |
| Withdrew: Insufficient clinical response | 3 |
| Milestone | Sildenafil |
|---|---|
| Started | 3 |
| Completed | 1 |
| Not completed | 2 |
| Withdrew: Coil embolization | 1 |
| Withdrew: Change of treatment plan | 1 |
PVRI equals pulmonary vascular resistance (PVR) times body surface area (BSA) (PVRI = PVR\*BSA). PVR is the resistance to blood flow through the pulmonary circulation and it was measured in Wood units. Wood unit =80 dyne\*seconds per centimetre\^5 (dyne\*sec/cm\^5).
| wood units*meter^2 | Sildenafil |
|---|---|
| Baseline | 18.567 ± 11.7629 |
| Change at Week 16 | -4.113 ± 6.3770 |
It was a hemodynamic parameter and measured using a pressure transducer positioned at the mid-axillary line with the participant in the supine position.
| millimeter of mercury (mmHg) | Sildenafil |
|---|---|
| Baseline | 58.5 ± 22.94 |
| Change at Week 16 | -6.5 ± 15.15 |
WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported.
| participants | Sildenafil |
|---|---|
| Baseline: Class I | 2 ± 0.58 |
| Baseline: Class II | 3 ± 0.58 |
| Baseline: Class III | 1 |
| Baseline: Class IV | 0 |
| Week 4: Improved | 1 |
| Week 4: No change | 5 |
| Week 4: Worsened | 0 |
WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported.
| participants | Sildenafil |
|---|---|
| Improved | 1 ± 0.71 |
| No change | 4 |
| Worsened | 0 |
WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported.
| participants | Sildenafil |
|---|---|
| Improved | 1 ± 0.71 |
| No change | 3 |
| Worsened | 0 |
BNP is produced by ventricular cardiomyocytes. It causes reduction in preload and blood pressure by vasodilatation.
| picogram per milliliter | Sildenafil |
|---|---|
| Baseline | 132.62 ± 135.080 |
| Change at Week 16 | -64.10 ± 129.638 |
NT pro-BNP is a cardiac marker, having the prognostic value for participants with heart failure or left ventricular dysfunction. Higher level of the marker was indicative of heart damage.
| picogram per milliliter | Sildenafil |
|---|---|
| Baseline | 843.03 ± 1120.900 |
| Change at Week 16 | -546.85 ± 1107.621 |
WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported.
| Participants | Sildenafil |
|---|---|
| Baseline: Class I | 1 |
| Baseline: Class II | 2 |
| Baseline: Class III | 0 |
| Baseline: Class IV | 0 |
| Week 28: Improved | 1 |
| Week 28: No Change | 2 |
| Week 28: Worsened | 0 |
| Week 40: Improved | 1 |
| Week 40: No Change | 2 |
| Week 40: Worsened | 0 |
| Week 52: Improved | 1 |
| Week 52: No Change | 2 |
| Week 52: Worsened | 0 |
| Week 64: Improved | 1 |
| Week 64: No Change | 1 |
| Week 64: Worsened | 0 |
| Week 76: Improved | 1 |
| Week 76: No Change | 0 |
| Week 76: Worsened | 1 |
| Week 88: Improved | 1 |
| Week 88: No Change | 0 |
| Week 88: Worsened | 0 |
| Week 100: Improved | 1 |
| Week 100: No Change | 0 |
| Week 100: Worsened | 0 |
| Week 112: Improved | 1 |
| Week 112: No Change | 0 |
| Week 112: Worsened | 0 |
| Week 124: Improved | 1 |
| Week 124: No Change | 0 |
| Week 124:Worsened | 0 |
BNP is produced by ventricular cardiomyocytes. It causes reduction in preload and blood pressure by vasodilatation.
| picograms per milliliter | Sildenafil |
|---|---|
| Baseline | 100.17 ± 151.478 |
| Change at Week 52 | -85.17 ± 155.088 |
| Change at EoT | -85.17 ± 155.088 |
NT pro-BNP is a cardiac marker, having the prognostic value for participants with heart failure or left ventricular dysfunction. Higher level of the marker was indicative of heart damage.
| picograms per milliliter | Sildenafil |
|---|---|
| Baseline | 841.73 ± 1323.533 |
| Change at Week 52 | -754.90 ± 1335.370 |
| Change at EoT | -754.90 ± 1335.370 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-serious AEs.
| Participants | Sildenafil |
|---|---|
| AEs | 6 |
| SAEs | 0 |
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-serious AEs.
| Participants | Sildenafil |
|---|---|
| AEs | 3 |
| SAEs | 0 |
BP measurement is recorded as supine and sitting systolic and diastolic systemic blood pressure: 1) Systolic blood pressure when heart is contracting and it is the maximum arterial pressure during contraction of left ventricle. 2) Diastolic BP when heart is relaxing and it is the minimum arterial pressure during relaxation and dilation of ventricles. Only those categories in which at least 1 participant had data were reported.
| mmHg | Sildenafil |
|---|---|
| Baseline: Supine Systolic BP | 95.4 ± 13.41 |
| Baseline: Supine Diastolic BP | 55.8 ± 10.87 |
| Baseline: Sitting Systolic BP | 110.0 |
| Baseline: Sitting Diastolic BP | 60.0 |
| Change at Week 4: Supine Systolic BP | 5.6 ± 9.91 |
| Change at Week 4: Supine Diastolic BP | 1.6 ± 13.65 |
| Change at Week 4: Sitting Systolic BP | 16.0 |
| Change at Week 4: Sitting Diastolic BP | 23.0 |
| Change at Week 8: Supine Systolic BP | 7.8 ± 14.93 |
| Change at Week 8: Supine Diastolic BP | 2.3 ± 12.28 |
| Change at Week 8: Sitting Systolic BP | -6.0 |
| Change at Week 8: Sitting Diastolic BP | -3.0 |
| Change at Week 16: Supine Systolic BP | 7.7 ± 17.62 |
| Change at Week 16: Supine Diastolic BP | -1.3 ± 12.22 |
| Change at Week 16: Sitting Systolic BP | 8.0 |
| Change at Week 16: Sitting Diastolic BP | 10.0 |
| Change at Week 28: Supine Systolic BP | 7.0 ± 19.31 |
| Change at Week 28: Supine Diastolic BP | 1.7 ± 9.29 |
| Change at Week 40: Supine Systolic BP | -7.5 ± 3.54 |
| Change at Week 40: Supine Diastolic BP | 2.0 ± 0.00 |
| Change at Week 52: Supine Systolic BP | 2.0 ± 15.56 |
| Change at Week 52: Supine Diastolic BP | 10.0 ± 5.66 |
| Change at Week 64: Supine Systolic BP | 1.0 |
| Change at Week 64: Supine Diastolic BP | 8.0 |
| Change at Week 76: Supine Systolic BP | -13.0 |
| Change at Week 76: Supine Diastolic BP | 3.0 |
Only those categories in which at least 1 participant had data were reported.
| beats per minute (bpm) | Sildenafil |
|---|---|
| Baseline: Supine Heart rate | 100.2 ± 15.91 |
| Baseline: Sitting Heart rate | 96.0 |
| Change at Week 4: Supine Heart rate | -1.0 ± 12.08 |
| Change at Week 4: Sitting Heart rate | -22.0 |
| Change at Week 8: Supine Heart rate | -0.5 ± 9.11 |
| Change at Week 8: Sitting Heart rate | 0.0 |
| Change at Week 16: Supine Heart rate | 3.0 ± 28.69 |
| Change at Week 16: Sitting Heart rate | 4.0 |
| Change at Week 28: Supine Heart rate | 6.7 ± 14.36 |
| Change at Week 40: Supine Heart rate | 10.0 ± 16.97 |
| Change at Week 52: Supine Heart rate | -2.0 ± 11.31 |
| Change at Week 64: Supine Heart rate | 17.0 |
| Change at Week 76: Supine Heart rate | -8.0 |
Laboratory abnormality criteria: Hematology (hemoglobin, hematocrit, red blood cell count \[less than {\<}\]0.8\*lower limit of normal \[LLN\]; platelets \<0.5\*LLN, greater than \[\>\]1.75\*upper limit of normal \[ULN\], white blood cells \<0.6\*LLN, \>1.5\*ULN; lymphocytes, neutrophils \<0.8\*LLN, \>1.2\*ULN, eosinophils, basophils, monocytes \>1.2\*ULN); liver function (total and direct bilirubin \>1.5\*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN, total protein, albumin \<0.8\*LLN, \>1.2\*ULN); renal (creatinine, blood urea nitrogen \>1.3\*ULN); electrolytes (sodium \<0.95\*LLN, \>1.05\*ULN, potassium, chloride \<0.9\*LLN, \>1.1\*ULN; other (glucose \<0.6\*LLN or \>1.5\*ULN ); urinalysis (dipstick) urine glucose, urine protein, urine blood/Hemoglobin, \[greater than or equal to {\>=}1\].
| Participants | Sildenafil |
|---|---|
| Number of Participants With Laboratory Abnormalities | 4 |
Criteria for clinically significant abnormality in ECG parameters: Maximum corrected QT interval (QTc) from 450 millisecond (msec) to less than (\<) 480 msec, Maximum QTcB interval (Bazett's Correction) from 450 msec to \<480 msec, Maximum QTcF interval (Fredericia's Correction) from 450 msec to \<480 msec, maximum QTc interval increase from baseline of 30 msec to \<60 msec and \>=60 msec.
| Participants | Sildenafil |
|---|---|
| Screening | 4 |
| Week 16 | 5 |
| Week 52 | 1 |
| End of Treatment | 1 |
Ocular examination measures included external examination of the eye, funduscopy, assessments of visual acuity, and color vision. Ocular examination findings were considered abnormal based on investigator's decision.
| Participants | Sildenafil |
|---|---|
| Number of Participants With Ocular Examination Abnormalities | 0 |
| mmHg | Sildenafil |
|---|---|
| Baseline: Systolic Pressure | 82.5 ± 35.51 |
| Baseline: Diastolic Pressure | 42.0 ± 18.19 |
| Change at Week 16: Systolic Pressure | -9.8 ± 18.01 |
| Change at Week 16: Diastolic Pressure | -3.5 ± 13.99 |
| mmHg | Sildenafil |
|---|---|
| Baseline: Systolic Pressure | 95.3 ± 15.20 |
| Baseline: Diastolic Pressure | 60.2 ± 19.30 |
| Change at Week 16: Systolic Pressure | 0.3 ± 10.21 |
| Change at Week 16: Diastolic Pressure | -1.5 ± 14.25 |
The resistance to blood flow through the pulmonary circulation is known as PVR. It is largely influenced by the caliber of the pulmonary arteries and capillaries and was measured in terms of Wood units. Wood unit =80 dyne\*seconds per centimetre\^5 (dyne\*sec/cm\^5).
| Wood units | Sildenafil |
|---|---|
| Baseline | 21.372 ± 11.3408 |
| Change at Week 16 | -6.145 ± 10.3499 |
RAP is the blood pressure in the right atrium of the heart. It reflects the amount of blood returning to the heart and the ability of the heart to pump the blood into the arterial system. RAP was measured using a pressure transducer positioned at the mid-axillary line with the participant in the supine position.
| mmHg | Sildenafil |
|---|---|
| Baseline | 6.5 ± 2.88 |
| Change at Week 16 | 1.3 ± 2.36 |
PCWP was measured by pulmonary artery catheterization and provided an indirect measure of left atrial pressure.
| mmHg | Sildenafil |
|---|---|
| Baseline | 8.5 ± 0.84 |
| Change at Week 16 | 2.5 ± 1.00 |
Cardiac output is simply the amount of blood pumped by the heart per minute.
| liter per minute | Sildenafil |
|---|---|
| Baseline | 2.620 ± 0.9879 |
| Change at Week 16 | 0.420 ± 0.9076 |
Cardiac index is a hemodynamic parameter that relates the cardiac output from left ventricle in one minute to BSA, thus relating heart performance to the size of the individual. CI was calculated as cardiac output in systemic circulation divided by BSA.
| liter per minute per meter square | Sildenafil |
|---|---|
| Baseline | 3.070 ± 0.7460 |
| Change at Week 16 | 0.658 ± 1.8912 |
The resistance to blood flow through the systemic circulation is known as SVR. This can be used in measuring blood pressure, blood flow and cardiac function and measured in terms of Wood units. Wood unit =80 dyne\*seconds per centimetre\^5 (dyne\*sec/cm\^5).
| Wood units | Sildenafil |
|---|---|
| Baseline | 26.545 ± 3.0768 |
| Change at Week 16 | -3.403 ± 4.4409 |
SVRI equals systemic vascular resistance (SVR) times BSA. SVR is the resistance to blood flow through the systemic circulation and it was measured in Wood units. Wood unit =80 dyne\*seconds per centimetre\^5 (dyne\*sec/cm\^5).
| Wood units*meter^2 | Sildenafil |
|---|---|
| Baseline | 23.855 ± 12.1480 |
| Change at Week 16 | -2.378 ± 3.9096 |
SvO2 is the percentage of mixed venous oxygen (amount of oxygen bound to hemoglobin in venous blood). Change from baseline in percentage of mixed venous oxygen was reported in this outcome measure.
| percentage of mixed venous oxygen | Sildenafil |
|---|---|
| Baseline | 65.30 ± 8.549 |
| Change at Week 16 | 5.38 ± 12.426 |
SaO2 is the percentage of arterial oxygen (amount of oxygen bound to hemoglobin in arterial blood). Change from baseline in percentage of arterial oxygen was reported in this outcome measure.
| percentage of arterial oxygen | Sildenafil |
|---|---|
| Baseline | 95.08 ± 2.730 |
| Change at Week 16 | -0.80 ± 1.691 |
UK-103,320 was the main metabolite of Sildenafil and was produced by cytochrome P450 3A4.
| nanogram per milliliter (ng/mL) | Sildenafil |
|---|---|
| Sildenafil | 138.1 ± 73 |
| UK-103,320 | 73.66 ± 48 |
UK-103,320 was the main metabolite of Sildenafil and was produced by cytochrome P450 3A4.
| nanogram*hour per millimeter | Sildenafil |
|---|---|
| Sildenafil | 338.9 ± 54 |
| UK-103,320 | 210.2 ± 74 |
UK-103,320 was the main metabolite of Sildenafil and was produced by cytochrome P450 3A4.
| hour | Sildenafil |
|---|---|
| Sildenafil | 1.00 (1.00 to 1.97) |
| UK-103,320 | 1.00 (1.00 to 1.97) |
Terminal half-life is the time measured for the plasma concentration to decrease by one half of its original concentration. UK-103,320 was a main metabolite of sildenafil and was produced by cytochrome P450 3A4.
| hour | Sildenafil |
|---|---|
| Sildenafil | 1.785 (1.63 to 1.94) |
| UK-103,320 | 2.110 (2.04 to 3.26) |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
| liter per hour | Sildenafil |
|---|---|
| Apparent Oral Clearance (CL/F) of Sildenafil | 41.73 ± 77 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
| liter | Sildenafil |
|---|---|
| Apparent Volume of Distribution (Vz/F) of Sildenafil | 77.90 (62.4 to 93.4) |
Acceleration time and ejection time are quantitative Doppler parameters and ratio of acceleration time to ejection time is a useful tool to evaluate the severity of aortic stenosis.
| ratio | Sildenafil |
|---|---|
| Baseline | 0.3038 ± 0.09675 |
| Change at Week 16 | 0.0175 ± 0.10261 |
The right ventricular Tei Index is an index of myocardial performance. It is defined as the sum of isovolumic contraction time and isovolumic relaxation time divided by the ejection time.
| ratio | Sildenafil |
|---|---|
| Baseline | 0.7540 ± 0.48602 |
| Change at Week 16 | -0.0440 ± 0.37618 |
| centimeter (cm) | Sildenafil |
|---|---|
| Baseline | 3.37 ± 1.216 |
| Change at Week 16 | -0.40 ± 0.408 |
The tricuspid valve lies between the right atrium and the right ventricle and is placed in a more apical position than the mitral valve. The annulus separates the right atrium from the right ventricle. Change from baseline in tricuspid valve annulus size (in cm) was reported in this outcome measure.
| cm | Sildenafil |
|---|---|
| Baseline | 2.190 ± 0.5636 |
| Change at Week 16 | -0.103 ± 0.3727 |
Tricuspid regurgitation (insufficiency) is the failure of the tricuspid valve to close properly during systole, leading to the leaking of blood from the right ventricle into the right atrium. Change from baseline in TR-PG peak (in mmHg) was reported in this outcome measure.
| mmHg | Sildenafil |
|---|---|
| Baseline | 73.0 ± 39.31 |
| Change at Week 16 | -6.0 ± 33.94 |
Pulmonary regurgitation (PR) or insufficiency is a valvular heart disease characterized by an incomplete closure of the pulmonary valve leading to a diastolic reflux into the right ventricle. Change from baseline in PR-PG end-diastole (in mmHg) was reported in this outcome measure.
| mmHg | Sildenafil |
|---|---|
| Baseline | 29.0 ± 14.73 |
| Change at Week 16 | 3.5 ± 13.44 |
Pericardial effusion is the presence of an abnormal amount of fluid in the pericardial cavity, as determined by echocardiography.
| participants | Sildenafil |
|---|---|
| Number of Participants With Pericardial Effusion | 0 |
Tricuspid annular plane systolic excursion is a parameter depicting global right ventricular function. Change from baseline in TAPSE (in cm) was reported in this outcome measure.
| cm | Sildenafil |
|---|---|
| Baseline | 1.47 ± 0.437 |
| Change at Week 16 | 0.18 ± 0.320 |
Collected over Baseline up to 28 days after last dose of study drug (maximum duration of treatment: 119.6 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sildenafil | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Event | Sildenafil |
|---|---|
| BronchitisInfections and infestations | 3/6 |
| NasopharyngitisInfections and infestations | 3/6 |
| Upper respiratory tract infectionInfections and infestations | 3/6 |
| DiarrhoeaGastrointestinal disorders | 2/6 |
| GastroenteritisInfections and infestations | 2/6 |
| HeadacheNervous system disorders | 2/6 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/6 |
| Cardiac failureCardiac disorders | 1/6 |
| Conjunctivitis allergicEye disorders | 1/6 |
| Dental cariesGastrointestinal disorders | 1/6 |
Efficacy analysis set included all participants who received at least 1 dose of study drug.
| Age, Categorical(Participants) | Sildenafil |
|---|---|
| <=18 years | 6 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age, Continuous(years) | Sildenafil |
|---|---|
| Mean | 6.7 ± 5.4 |
| Sex: Female, Male(Participants) | Sildenafil |
|---|---|
| Female | 3 |
| Male | 3 |
Ran from Aug 2012 to primary completion in May 2016, 44 months.
Results were first posted in Apr 2017, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Pulmonary Arterial Hypertension →
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →